Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

Journal of Palliative Medicine

Volumn 9, Issue 1, 2006, Pages 29-40

  Raskin, Joel ^a   Smith, Timothy R ^b   Wong, Kar ^c   Pritchett, Yili Lu ^a   D'Souza, Deborah N ^a   Iyengar, Smriti ^a   Wernicke, J F ^a  

^a ELI LILLY AND COMPANY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Eli Lilly and Company ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMITRIPTYLINE; AMLODIPINE BESYLATE; ATENOLOL; ATORVASTATIN; AZITHROMYCIN; CALCIUM; CARBAMAZEPINE; CLOPIDOGREL; DULOXETINE; ESOMEPRAZOLE; FUROSEMIDE; GABAPENTIN; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN GLARGINE; INSULIN LISPRO; LANSOPRAZOLE; LIPID; LISINOPRIL; METFORMIN; METOPROLOL SUCCINATE; MULTIVITAMIN; NORADRENALIN UPTAKE INHIBITOR; PANTOPRAZOLE; PARACETAMOL; PIOGLITAZONE; PLACEBO; QUINAPRIL; RAMIPRIL; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SIMVASTATIN; SYNTHOID; TAMSULOSIN; UNINDEXED DRUG; VALSARTAN; VENLAFAXINE;

ACUTE HEART INFARCTION; ADULT; AGED; AGITATION; ARTICLE; BALANCE DISORDER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMENTIA; DIABETIC KETOACIDOSIS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSPNEA; ERYTHEMA; EUROPEAN QUALITY OF LIFE 5 DIMENSION QUESTIONNAIRE; FALLING; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCALCEMIA; INCIDENCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINAL DYSMOTILITY; LONG TERM CARE; LUNG EMBOLISM; MALE; NAUSEA; NERVE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PAIN; PARKINSON DISEASE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TREATMENT OUTCOME; URINE RETENTION; VOMITING;

EID: 32044443644     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.9.29     Document Type: Article

References (38)

1. National Diabetes Information Clearinghouse (NDIC): National Diabetes Statistics: Total prevalence of diabetes in the United States, All Ages, 2002. (www.diabetes.niddk.nih.gov/dm/pubs/statistics/ index.htm#7) (Last accessed November 8, 2005).
2. Clark CM, Lee DA: Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332:1210-1217.
3. Boulton AJM, Rayaz AM, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-1486.
4. Eastman RC: Diabetes in America, 2nd ed. NIH Publication No. 95-1468, 1995, pp. 339-348.
5. Callisi PT, Jaber LA: Peripheral diabetic neuropathy: current concepts in treatment. Ann Pharmacother 1995;29:769-777.
6. Courteix C, Eschalier A, Laverenne J: Streptozocin-induced diabetic rats: Behavioral evidence for a model of chronic pain. Pain 1993;53:81-88.
7. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-363.
8. Basbaum AI, Fields HL: Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-338.
9. Clark FM, Proudfit HK: The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: Anatomical evidence that A5 neurons modulate nociception. Brain Res 1993;616:200-210.
10. Coderre TJ, Katz J: Peripheral and central hyperextitability: Differential signs and symptoms in persistent pain. Behav Brain Sci 1997;20:404-419.
11. Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, Dubner R: Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain 1991;45:3-9.
12. Lynch ME: Antidepressants as analgesics: A review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-36.
13. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
14. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS: Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003;60:1284-1289.
15. Backonja M-M: Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002;59(Suppl 2):S14-S17.
16. Tremont-Lukats I, Megeff C, Backonja M-M: Anticonvulsants for neuropathic pain, syndromes: Mechanisms of action and place in therapy. Drugs 2000;60:1029-1052.
17. Stone KJ, Viera AJ, Parman CL: Off-label applications for SSRIs. Am Fam Physician 2003;68:498-504.
18. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J: Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-78.
19. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 2003;60:927-934.
20. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290:1757-1762.
21. Wong DT, Bymaster FP: Dual serotonin and noradrenaline uptake inhibitor class of antidepressants-Potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222.
22. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315.
23. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390.
24. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 2002;63:225-231.
25. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399.
26. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-1244.
27. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118.
28. Wernicke J, Lu Y, D'Souza D, Waninger A, Tran P: Antidepressants: Duloxetine at doses of 60 mg QD and 60 mg BID is effective in the treatment of diabetic neuropathic pain (DNP). J Pain 2004;5(Suppl 1):S48.
29. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-356.
30. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA: A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289.
31. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
32. Kind P: The EuroQoL instrument: an index of health-related quality of life. In: Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996, pp. 191-201.
33. Wernicke J, Rosen A, Lu Y, Lee T, Iyengar S, Knopp K, Goldstein D: The safety of duloxetine in the long-term treatment of diabetic neuropathic pain. J Pain 2004; 5(Issue 3, Suppl 1), S48; Presentation at the American Academy of Pain Medicine. Orlando, FL: March 3-7, 2004.
34. Raskin J, Wang F, Pritchett YL, Goldstein DJ: Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study. Pain Med (in press).
35. National Center for Health Statistics: Health, United States, 2004 With Chartbook on Trends in the Health of Americans. Hyattsville, MD: 2004.
36. National Diabetes Information Clearinghouse (NDIC): National Diabetes Statistics: Deaths Among People with Diabetes, United States, 2000. 〈www. diabetes.niddk.nih.gov/dm/pubs/statistics/index.h tm#7〉 (Last accessed November 8, 2005).
37. Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ: Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study. Neuropsychopharmacology 2003;28:1685-1693.
38. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132.